Torre, L. A. et al. Global cancer statistics, 2012. CA Cancer J. Clin. 65, 87–108 (2015).
Ferlay, J. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J. Cancer 127, 2893–2917 (2010).
Cunningham, D. et al. Colorectal cancer. The Lancet; 375: 1030–1047.
American Cancer Society. https://wwwcancerorg/cancer/colon-rectal-cancer/detection-diagnosis-staging/survival-rateshtml. Accessed 2 March 2017.
Logan, C. Y. & Nusse, R. The Wnt signaling pathway in development and disease. Annu. Rev. Cell. Dev. Biol. 20, 781–810 (2004).
Yang, L. et al. Wnt modulates MCL1 to control cell survival in triple negative breast cancer. BMC Cancer 14, 124 (2014).
de Sousa, E. M., Vermeulen, L., Richel, D. & Medema, J. P. Targeting Wnt signaling in colon cancer stem cells. Clin. Cancer Res. 17, 647–653 (2011).
Kurayoshi, M. et al. Expression of Wnt-5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion. Cancer Res. 66, 10439–10448 (2006).
Gupta, S. et al. FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res. 70, 6735–6745 (2010).
Howe, L. R. & Brown, A. M. Wnt signaling and breast cancer. Cancer Biol. Ther. 3, 36–41 (2004).
El Wakil, A. & Lalli, E. The Wnt/beta-catenin pathway in adrenocortical development and cancer. Mol. Cell. Endocrinol. 332, 32–37 (2011).
Mikels, A. J. & Nusse, R. Wnts as ligands: processing, secretion and reception. Oncogene 25, 7461–7468 (2006).
Klaus, A. & Birchmeier, W. Wnt signalling and its impact on development and cancer. Nat. Rev. Cancer 8, 387–398 (2008).
Lin, C. M. et al. Apigenin-induced lysosomal degradation of beta-catenin in Wnt/beta-catenin signaling. Sci. Rep. 7, 372 (2017).
He, T. C. et al. Identification of c-MYC as a target of the APC pathway. Science 281, 1509–1512 (1998).
Morin, P. J. et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275, 1787–1790 (1997).
Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487 : 330–337.
Reya, T. & Clevers, H. Wnt signalling in stem cells and cancer. Nature 434, 843–850 (2005).
Voloshanenko, O. et al. Wnt secretion is required to maintain high levels of Wnt activity in colon cancer cells. Nat. Commun. 4, 2610 (2013).
Nguyen, G. et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J. Clin. Invest. 109, 1417–1427 (2002).
Cruciat, C. M. et al. Requirement of prorenin receptor and vacuolar H+-ATPase-mediated acidification for Wnt signaling. Science 327, 459–463 (2010).
Ohba, K. et al. Expression of (pro)renin receptor in breast cancers and its effect on cancercell proliferation. Biomed. Res. 35, 117–126 (2014).
Shibayama, Y. et al. Pro)renin receptor is crucial for Wnt/beta-catenin-dependent genesis of pancreatic ductal adenocarcinoma. Sci. Rep. 5, 8854 (2015).
Kouchi, M. et al. (Pro)renin receptor is crucial for glioma development via the Wnt/beta-catenin signaling pathway. J. Neurosurg. 127, 819–828 (2017).
Yamamoto, H. et al. Increased expression of (pro)renin receptor in aldosterone-producing adenomas. Peptides 49, 68–73 (2013).
Lee, M. A. et al. Wnt3a expression is associated with MMP-9 expression in primary tumour and metastatic site in recurrent or stage IV colorectal cancer. BMC Cancer 14, 125 (2014).
Hirose, T. et al. Gene expression of (pro)renin receptor is upregulated in hearts and kidneys of rats with congestive heart failure. Peptides 30, 2316–2322 (2009).
Takahashi, K. et al. Expression of (pro)renin receptor in human kidneys with end-stage kidney disease due to diabetic nephropathy. Peptides 31, 1405–1408 (2010).
Qi, L. et al. Wnt3a expression is associated with epithelial-mesenchymal transition and promotes colon cancer progression. J. Exp. Clin. Cancer Res. 33, 107 (2014).
Adams, E. J., Green, J. A., Clark, A. H. & Youngson, J. H. Comparison of different scoring systems for immunohistochemical staining. J. Clin. Pathol. 52, 75–77 (1999).
Wei, W., Li, M., Wang, J., Nie, F. & Li, L. The E3 ubiquitin ligase ITCH negatively regulates canonical Wnt signaling by targeting dishevelled protein. Mol. Cell. Biol. 32, 3903–3912 (2012).
Wang, J. et al. High glucose augments angiotensinogen in human renal proximal tubular cells through hepatocyte nuclear factor-5. PLoS ONE 12, e0185600 (2017).
Workman, P. et al. Guidelines for the welfare and use of animals in cancer research. Br. J. Cancer 102, 1555–1577 (2010).
Marisa, L. et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med. 10, e1001453 (2013).
Arundhathi, A. et al. Prorenin receptor acts as a potential molecular target for pancreatic ductal adenocarcinoma diagnosis. Oncotarget 7, 55437–55448 (2016).
Wang, Y.-D. et al. Downregulation of human Wnt3 in gastric cancer suppresses cell proliferation and induces apoptosis. Onco. Targets Ther. 9, 3849–3860 (2016).
Li, Y., Lu, W., He, X., Schwartz, A. L. & Bu, G. LRP6 expression promotes cancer cell proliferation and tumorigenesis by altering beta-catenin subcellular distribution. Oncogene 23, 9129–9135 (2004).
Liu, C. C., Prior, J., Piwnica-Worms, D. & Bu, G. LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy. Proc. Natl Acad. Sci. USA 107, 5136–5141 (2010).
Bernhard, S. M. et al. The (pro)renin receptor ((P)RR) can act as a repressor of Wnt signalling. Biochem. Pharmacol. 84, 1643–1650 (2012).